News
Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy ...
Revumenib for relapsed/refractory acute leukemias with KMT2A translocation is cost-neutral for health plans, but traditional ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback